The effect of adalimumab on key drivers in the pathogenesis of psoriasis

British Journal of Dermatology

Volumn 170, Issue 3, 2014, Pages 571-580

  Hendriks, A G M ^a   Van Der Velden, H M J ^a   Wolberink, E A W ^a   Seyger, M M B ^a   Schalkwijk, J ^a   Zeeuwen, P L J M ^a   De Jong, E M G J ^a   Pasch, M C ^a   Van Erp, P E J ^a   Van De Kerkhof, P C M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CD3 ANTIGEN; CORTICOSTEROID; CYCLOSPORIN; DITHRANOL; EFALIZUMAB; ELAFIN; ELASTASE; ETANERCEPT; INFLIXIMAB; INTERLEUKIN 17; INTERLEUKIN 8; KI 67 ANTIGEN; MESSENGER RNA; METHOTREXATE; PSORALEN; RETINOID; T6 ANTIGEN; TRANSCRIPTION FACTOR T BET; VITAMIN D; BIOLOGICAL MARKER; DERMATOLOGICAL AGENT; GENETIC MARKER; MONOCLONAL ANTIBODY;

ADAPTIVE IMMUNITY; ADULT; AGED; ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL ARTICLE; EPIDERMIS; FEMALE; GENE EXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; INNATE IMMUNITY; LANGERHANS CELL; MALE; MIDDLE AGED; OBSERVATIONAL STUDY; OPEN STUDY; PHOTOTHERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSORIASIS AREA AND SEVERITY INDEX; PSORIASIS VULGARIS; PUNCH BIOPSY; TREATMENT DURATION; ULTRAVIOLET A RADIATION; DRUG EFFECTS; GENETIC MARKER; IMMUNOLOGY; METABOLISM; ONSET AGE; PSORIASIS; REAL TIME POLYMERASE CHAIN REACTION; TREATMENT OUTCOME;

ADAPTIVE IMMUNITY; ADULT; AGE OF ONSET; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOLOGICAL MARKERS; DERMATOLOGIC AGENTS; FEMALE; GENE EXPRESSION; GENETIC MARKERS; HUMANS; IMMUNITY, INNATE; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; LANGERHANS CELLS; MALE; MIDDLE AGED; PSORIASIS; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; TREATMENT OUTCOME;

EID: 84896082361     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.12705     Document Type: Article

References (28)

1. Krueger GG, Bergstresser PR, Lowe NJ, et al,. Psoriasis. J Am Acad Dermatol 1984; 11: 937-47. (Pubitemid 15204899)
2. Braun-Falco O,. Burg G [Inflammatory infiltrate in psoriasis vulgaris. A cytochemical study]. Arch Klin Exp Dermatol 1970; 236: 297-314 (in German).
3. Bos JD, Hulsebosch HJ, Krieg SR, et al,. Immunocompetent cells in psoriasis. In situ immunophenotyping by monoclonal antibodies. Arch Dermatol Res 1983; 275: 181-9. (Pubitemid 13056614)
4. Nestle FO, Nickoloff BJ,. Role of dendritic cells in benign and malignant lymphocytic infiltrates of the skin. Dermatol Clin 1994; 12: 271-82. (Pubitemid 24149710)
5. Griffiths CE, Powles AV, Leonard JN, et al,. Clearance of psoriasis with low dose cyclosporin. Br Med J 1986; 293: 731-2. (Pubitemid 16025288)
6. Prinz J, Braun-Falco O, Meurer M, et al,. Chimaeric CD4 monoclonal antibody in treatment of generalised pustular psoriasis. Lancet 1991; 338: 320-1.
7. Griffiths CE, Barker JN,. Pathogenesis and clinical features of psoriasis. Lancet 2007; 370: 263-71. (Pubitemid 47069537)
8. Blauvelt A,. T-helper 17 cells in psoriatic plaques and additional genetic links between IL-23 and psoriasis. J Invest Dermatol 2008; 128: 1064-7. (Pubitemid 351543223)
9. Zaba LC, Fuentes-Duculan J, Eungdamrong NJ, et al,. Psoriasis is characterized by accumulation of immunostimulatory and Th1/Th17 cell-polarizing myeloid dendritic cells. J Invest Dermatol 2009; 129: 79-88.
10. Bergboer JG, Zeeuwen PL, Schalkwijk J,. Genetics of psoriasis: evidence for epistatic interaction between skin barrier abnormalities and immune deviation. J Invest Dermatol 2012; 132: 2320-1.
11. Leonardi CL, Powers JL, Matheson RT, et al,. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003; 349: 2014-22. (Pubitemid 37448924)
12. Esposito M, Giunta A, Mazzotta A, et al,. Efficacy and safety of subcutaneous anti-tumor necrosis factor-alpha agents, etanercept and adalimumab, in elderly patients affected by psoriasis and psoriatic arthritis: an observational long-term study. Dermatology 2012; 225: 312-19.
13. Fernandez-Torres RM, Paradela S, Fonseca E,. Long-term response to etanercept monotherapy in moderate to severe psoriasis: assessment in daily practice by the maintenance of low values of PASI and BSA. J Dermatolog Treat 2014; 25: 54-6.
14. Abbott Laboratories. Adalimumab. Summary of product characteristics, 2013. Queenborough, U.K.: Abbott Laboratories. Available from: http://www.emea.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/ human/000481/WC500050870.pdf (last accessed 11 December 2013).
15. Marble DJ, Gordon KB, Nickoloff BJ,. Targeting TNFalpha rapidly reduces density of dendritic cells and macrophages in psoriatic plaques with restoration of epidermal keratinocyte differentiation. J Dermatol Sci 2007; 48: 87-101. (Pubitemid 47381571)
16. Gordon KB, Bonish BK, Patel T, et al,. The tumour necrosis factor-alpha inhibitor adalimumab rapidly reverses the decrease in epidermal Langerhans cell density in psoriatic plaques. Br J Dermatol 2005; 153: 945-53. (Pubitemid 41540759)
17. Soegaard-Madsen L, Johansen C, Iversen L, et al,. Adalimumab therapy rapidly inhibits p38 mitogen-activated protein kinase activity in lesional psoriatic skin preceding clinical improvement. Br J Dermatol 2010; 162: 1216-23.
18. Johansen C, Vinter H, Soegaard-Madsen L, et al,. Preferential inhibition of the mRNA expression of p38 mitogen-activated protein kinase regulated cytokines in psoriatic skin by anti-TNFalpha therapy. Br J Dermatol 2010; 163: 1194-204.
19. Chren MM, Lasek RJ, Quinn LM, et al,. Skindex, a quality-of-life measure for patients with skin disease: reliability, validity, and responsiveness. J Invest Dermatol 1996; 107: 707-13. (Pubitemid 26371086)
20. Hendriks AGM, Keijsers RRMC, Seyger MMB, et al,. Cutaneous application of leukotriene B4 as an in vivo model of psoriasis-like skin inflammation: an immunohistological study. Skin Pharmacol Physiol 2014; 27: 120-126.
21. de Jongh GJ, Zeeuwen PL, Kucharekova M, et al,. High expression levels of keratinocyte antimicrobial proteins in psoriasis compared with atopic dermatitis. J Invest Dermatol 2005; 125: 1163-73.
22. Franssen ME, Zeeuwen PL, Vierwinden G, et al,. Phenotypical and functional differences in germinative subpopulations derived from normal and psoriatic epidermis. J Invest Dermatol 2005; 124: 373-83. (Pubitemid 40175885)
23. Livak KJ, Schmittgen TD,. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001; 25: 402-8. (Pubitemid 34164012)
24. Bovenschen HJ, Vissers WH, Seyger MM, et al,. Selective persistence of dermal CD8+ T cells in lesional plaque psoriasis after clobetasol-17 propionate treatment. Acta Derm Venereol 2005; 85: 113-17. (Pubitemid 40477659)
25. Lin AM, Rubin CJ, Khandpur R, et al,. Mast cells and neutrophils release IL-17 through extracellular trap formation in psoriasis. J Immunol 2011; 187: 490-500.
26. Christophers E,. Explaining phenotype heterogeneity in patients with psoriasis. Br J Dermatol 2008; 158: 437-41. (Pubitemid 351239153)
27. Hendriks AGM, Keijsers RRMC, Seyger MMB, van Erp PEJ, van de Kerkhof PCM,. Are newly discovered drivers of immune mediated skin disorders expressed in normal skin regenerating from standardized surface injury? Dermatology 2013; (in press)
28. Johansen C, Funding AT, Otkjaer K, et al,. Protein expression of TNF-alpha in psoriatic skin is regulated at a posttranscriptional level by MAPK-activated protein kinase 2. J Immunol 2006; 176: 1431-8. (Pubitemid 43134285)